Developer docs
API playgroundTry for free, no card

Search company profiles

Almeda Ventures

Full company profile

uuid0009cwa

Namestring
Almeda Ventures
Legal namestring
Almeda Ventures
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA on the Tel Aviv Stock Exchange) and the first HealthTech-focused public partnership of its kind in Israel. Founded in 2020 and headquartered in Tel Aviv, the firm invests globally across three verticals — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with proven clinical concepts and validated business models. Its portfolio of approximately ten disclosed companies spans surgical AR (Augmedics xvision), minimally invasive robotic instruments (FlexDex), soft tissue repair (Nurami Medical), neuromuscular stimulation (Virility), cancer care navigation (Belong), metabolic monitoring (Lumen), AI-driven elder care (Sensi.AI), radiotherapy protection (BioProtect), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed). The firm does not develop proprietary technology products; instead, its offering is investment capital combined with strategic, regulatory, clinical, IP, and reimbursement support delivered through a lean core team and a specialized advisory bench.

Revenue mechanics for Almeda are those of an investment vehicle rather than an operating business: returns accrue to unit holders through capital appreciation and exit events (acquisitions, IPOs) across the portfolio, supplemented by participation in follow-on rounds. The core team — Founding Partners Dr. Irit Yaniv (also Chairperson) and Amir Blatt, CEO Manor Zemer, CFO Efrat Hess, and Director Tzahi Sultan — is supported by named advisors covering clinical (Dr. Ori Ben-Yehuda), reimbursement (Dr. Joel Brill), IP (Dr. Michal Fisher), and regulatory (Dr. Susan Alpert, ex-FDA and Medtronic) domains. Distribution and deal sourcing rely on direct networks, industry events (Biomed Israel, ICI), LinkedIn, and the corporate website. Co-investment relationships with Accelmed and Olive Tree Ventures alumni connections provide a deal-flow pipeline, while the TASE listing gives the entity differentiated access to public capital relative to conventional closed-end Israeli VC funds.

Short descriptiontext

Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA) that invests globally in HealthTech — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with capital, regulatory, clinical, and strategic support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HealthTech venture capital, Medical device investment, Digital health funding, Bio-convergence investment, Public R&D partnership
Industry3 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Management Consulting Services54161
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Investment Advice6282
  • Services-Management Consulting Services8742
Product category
Venture Capital / HealthTech Investment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Almeda Ventures generates returns through equity investments in HealthTech companies. As a public R&D partnership listed on the Tel Aviv Stock Exchange (AMDA.TA), they benefit from capital appreciation of portfolio companies and potential exit events including acquisitions and IPOs.

almedaventures.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Almeda Ventures is the first HealthTech-focused public R&D partnership (TASE: AMDA.TA), investing globally in early- and growth-stage medical device, digital health, and bio-convergence companies. It deploys equity capital and provides strategic guidance, regulatory and reimbursement expertise, and access to a network of investors, strategics, and medical centers to help portfolio companies progress from clinical concept to commercial success and exit.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Almeda Ventures is a HealthTech-focused public R&D partnership (traded as AMDA.TA on the Tel Aviv Stock Exchange) that invests globally in medical devices, digital health, and bio-convergence. The company is not itself a product manufacturer; rather it provides investment and support to a portfolio of early- and growth-stage HealthTech companies. The portfolio includes ten distinct portfolio companies spanning surgical augmentation (Augmedics xvision), minimally invasive surgical instruments (FlexDex Surgical), neurological tissue repair (Nurami Medical), urology (Virility Medical), cancer care management (Belong), metabolic health monitoring (Lumen), AI-powered senior care quality (Sensi.AI), radiotherapy protection (BioProtect ProSpace Balloon System), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed).

Product and service1 record
1Almeda Ventures HealthTech R&D Partnership
CategoryVenture Capital / HealthTech Investment
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Almeda's Dr. Irit Yaniv is an active participant in the 8400 project (cohort 2), an Israeli healthcare innovation initiative.

2Life Science Women Forum
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-founded by Almeda's Dr. Irit Yaniv, a forum focused on women empowerment in the life sciences sector.

almedaventures.com
3We@Healthcare
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-founded by Almeda's Dr. Irit Yaniv, a women empowerment initiative in healthcare.

almedaventures.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Almeda's CEO Manor Zemer serves as a council member of Meuhedet Health Services, contributing expertise in investment strategy and governance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Accelmed is a global HealthTech-focused PE/VC group investing in commercial-stage and growth-stage medical companies. It is Almeda's closest direct peer — co-founders Dr. Irit Yaniv and Amir Blatt were Accelmed partners, and the firms continue to co-invest — making Accelmed the most structurally and thematically comparable entity.

TypeDirect peer
Description

Israel-based $170M digital health VC fund. Almeda CEO Manor Zemer was previously a Partner at OTV, and the funds share a focus on Israeli HealthTech. OTV is a direct peer in stage, geography, and vertical.

TypeDirect peer
Description

Israeli growth-stage venture fund investing in technology and healthcare. Qumra led Sensi.AI's $45M Series C with Almeda participating, making it a directly comparable co-investor and peer in the Israeli HealthTech growth space.

TypeDirect peer
Description

One of Israel's largest and most active venture capital firms with a dedicated HealthTech practice. Pitango invests across stages in Israeli medical device, digital health, and biotech companies — directly overlapping Almeda's investment focus and geography.

TypeDirect peer
Description

Israel-based global venture investing platform with active HealthTech and digital health portfolios. OurCrowd is a direct comparable in Israeli HealthTech venture deployment, particularly for early to growth-stage deals.

TypeBroad incumbent
Description

Large global software and HealthTech investor. Insight Partners co-invested in Sensi.AI alongside Almeda and is a broader incumbent in the digital health and growth equity space, competing for later-stage Israeli deals.

TypeDirect peer
Description

Growth-stage healthcare investor that led TailorMed's $40M round with Almeda participating. Windham is a directly comparable growth-equity peer in HealthTech with overlapping portfolio themes.

TypeDirect peer
Description

Israeli-listed (SGX) medical and agrifood technology incubator and investor. Trendlines is a direct peer in Israeli medtech early-stage investing and is itself publicly traded like Almeda, making it a structural as well as thematic comparable.

TypeBroad incumbent
Description

Global venture capital firm with a large Health Assurance / healthcare practice. While broader than Almeda, General Catalyst competes for the same digital health and bio-convergence deals and is a leading global HealthTech incumbent.

TypeRegional player
Description

Israel-based global HealthTech and life sciences investor founded by Marius Nacht. aMoon is a regional HealthTech peer with similar investment focus, Israeli roots, and global deployment — overlapping with Almeda in portfolio construction.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Almeda Ventures

Venture Capital / HealthTech Investmentalmedaventures.com

Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA) that invests globally in HealthTech — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with capital, regulatory, clinical, and strategic support.

What Almeda Ventures does

Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA on the Tel Aviv Stock Exchange) and the first HealthTech-focused public partnership of its kind in Israel. Founded in 2020 and headquartered in Tel Aviv, the firm invests globally across three verticals — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with proven clinical concepts and validated business models. Its portfolio of approximately ten disclosed companies spans surgical AR (Augmedics xvision), minimally invasive robotic instruments (FlexDex), soft tissue repair (Nurami Medical), neuromuscular stimulation (Virility), cancer care navigation (Belong), metabolic monitoring (Lumen), AI-driven elder care (Sensi.AI), radiotherapy protection (BioProtect), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed). The firm does not develop proprietary technology products; instead, its offering is investment capital combined with strategic, regulatory, clinical, IP, and reimbursement support delivered through a lean core team and a specialized advisory bench.

Revenue mechanics for Almeda are those of an investment vehicle rather than an operating business: returns accrue to unit holders through capital appreciation and exit events (acquisitions, IPOs) across the portfolio, supplemented by participation in follow-on rounds. The core team — Founding Partners Dr. Irit Yaniv (also Chairperson) and Amir Blatt, CEO Manor Zemer, CFO Efrat Hess, and Director Tzahi Sultan — is supported by named advisors covering clinical (Dr. Ori Ben-Yehuda), reimbursement (Dr. Joel Brill), IP (Dr. Michal Fisher), and regulatory (Dr. Susan Alpert, ex-FDA and Medtronic) domains. Distribution and deal sourcing rely on direct networks, industry events (Biomed Israel, ICI), LinkedIn, and the corporate website. Co-investment relationships with Accelmed and Olive Tree Ventures alumni connections provide a deal-flow pipeline, while the TASE listing gives the entity differentiated access to public capital relative to conventional closed-end Israeli VC funds.

Almeda Ventures firmographics

Firmographics
Name
Almeda Ventures
Legal name
Almeda Ventures
Website
https://almedaventures.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA) that invests globally in HealthTech — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with capital, regulatory, clinical, and strategic support.
Ownership category
akta.pro rank

Almeda Ventures industry classification

Industry
Product category
Venture Capital / HealthTech Investment
NAICS
Portfolio Management and Investment Advice (523940), Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)
SIC
Investment Advice (6282), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms

Keywords

  • HealthTech venture capital
  • Medical device investment
  • Digital health funding
  • Bio-convergence investment
  • Public R&D partnership

Where Almeda Ventures is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Almeda Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Investment Returns: Almeda Ventures generates returns through equity investments in HealthTech companies. As a public R&D partnership listed on the Tel Aviv Stock Exchange (AMDA.TA), they benefit from capital appreciation of portfolio companies and potential exit events including acquisitions and IPOs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Almeda Ventures product offering

Product offering

Core offering

Almeda Ventures is the first HealthTech-focused public R&D partnership (TASE: AMDA.TA), investing globally in early- and growth-stage medical device, digital health, and bio-convergence companies. It deploys equity capital and provides strategic guidance, regulatory and reimbursement expertise, and access to a network of investors, strategics, and medical centers to help portfolio companies progress from clinical concept to commercial success and exit.

Product overview

Almeda Ventures is a HealthTech-focused public R&D partnership (traded as AMDA.TA on the Tel Aviv Stock Exchange) that invests globally in medical devices, digital health, and bio-convergence. The company is not itself a product manufacturer; rather it provides investment and support to a portfolio of early- and growth-stage HealthTech companies. The portfolio includes ten distinct portfolio companies spanning surgical augmentation (Augmedics xvision), minimally invasive surgical instruments (FlexDex Surgical), neurological tissue repair (Nurami Medical), urology (Virility Medical), cancer care management (Belong), metabolic health monitoring (Lumen), AI-powered senior care quality (Sensi.AI), radiotherapy protection (BioProtect ProSpace Balloon System), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed).

Differentiator

Problem solved

Functional benefit

Products and services

  • Almeda Ventures HealthTech R&D Partnership

Companies that use Almeda Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Almeda Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Almeda Ventures partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor.

  • 8400 ProjectminorStrategic or Co-development PartnerAlmeda's Dr. Irit Yaniv is an active participant in the 8400 project (cohort 2), an Israeli healthcare innovation initiative.
  • Life Science Women ForumminorStrategic or Co-development PartnerCo-founded by Almeda's Dr. Irit Yaniv, a forum focused on women empowerment in the life sciences sector.
  • We@HealthcareminorStrategic or Co-development PartnerCo-founded by Almeda's Dr. Irit Yaniv, a women empowerment initiative in healthcare.
  • Meuhedet Health ServicesminorStrategic or Co-development PartnerAlmeda's CEO Manor Zemer serves as a council member of Meuhedet Health Services, contributing expertise in investment strategy and governance.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Almeda Ventures competitors and assessment

Company assessment

Direct peers

  • Accelmed: Accelmed is a global HealthTech-focused PE/VC group investing in commercial-stage and growth-stage medical companies. It is Almeda's closest direct peer — co-founders Dr. Irit Yaniv and Amir Blatt were Accelmed partners, and the firms continue to co-invest — making Accelmed the most structurally and thematically comparable entity.
  • Olive Tree Ventures (OTV): Israel-based $170M digital health VC fund. Almeda CEO Manor Zemer was previously a Partner at OTV, and the funds share a focus on Israeli HealthTech. OTV is a direct peer in stage, geography, and vertical.
  • Qumra Capital: Israeli growth-stage venture fund investing in technology and healthcare. Qumra led Sensi.AI's $45M Series C with Almeda participating, making it a directly comparable co-investor and peer in the Israeli HealthTech growth space.
  • Pitango Venture Capital: One of Israel's largest and most active venture capital firms with a dedicated HealthTech practice. Pitango invests across stages in Israeli medical device, digital health, and biotech companies — directly overlapping Almeda's investment focus and geography.
  • OurCrowd: Israel-based global venture investing platform with active HealthTech and digital health portfolios. OurCrowd is a direct comparable in Israeli HealthTech venture deployment, particularly for early to growth-stage deals.
  • Windham Capital Partners: Growth-stage healthcare investor that led TailorMed's $40M round with Almeda participating. Windham is a directly comparable growth-equity peer in HealthTech with overlapping portfolio themes.
  • Trendlines Group: Israeli-listed (SGX) medical and agrifood technology incubator and investor. Trendlines is a direct peer in Israeli medtech early-stage investing and is itself publicly traded like Almeda, making it a structural as well as thematic comparable.

Broad incumbents

  • Insight Partners: Large global software and HealthTech investor. Insight Partners co-invested in Sensi.AI alongside Almeda and is a broader incumbent in the digital health and growth equity space, competing for later-stage Israeli deals.
  • General Catalyst: Global venture capital firm with a large Health Assurance / healthcare practice. While broader than Almeda, General Catalyst competes for the same digital health and bio-convergence deals and is a leading global HealthTech incumbent.

Regional players

  • aMoon Fund: Israel-based global HealthTech and life sciences investor founded by Marius Nacht. aMoon is a regional HealthTech peer with similar investment focus, Israeli roots, and global deployment — overlapping with Almeda in portfolio construction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Almeda Ventures social profiles

Digital presence

Almeda Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Almeda Ventures leadership team

Management profile

Number of profiles

Profiles1 record

Almeda Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Almeda Ventures M&A and investment

M&A and investment

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almeda Ventures

What does Almeda Ventures do?

Almeda Ventures is the first HealthTech-focused public R&D partnership (TASE: AMDA.TA), investing globally in early- and growth-stage medical device, digital health, and bio-convergence companies. It deploys equity capital and provides strategic guidance, regulatory and reimbursement expertise, and access to a network of investors, strategics, and medical centers to help portfolio companies progress from clinical concept to commercial success and exit.

Is Almeda Ventures a public or private company?

Almeda Ventures is a public company. It is classified as public and is currently operating.

When was Almeda Ventures founded?

Almeda Ventures was founded in 2020. It employs 1 to 10 people.

Where is Almeda Ventures based?

Almeda Ventures is headquartered in Tel Aviv, Israel, in the Middle East region.

How does Almeda Ventures make money?

One revenue line is on record: investment Returns.

Who are Almeda Ventures's main competitors?

Direct peers on record are Accelmed, Olive Tree Ventures (OTV), Qumra Capital, Pitango Venture Capital, OurCrowd, Windham Capital Partners and Trendlines Group. Broad incumbents are Insight Partners and General Catalyst. aMoon Fund is listed as a regional player.

Does Almeda Ventures have an API?

No public API is recorded for Almeda Ventures.

What industry is Almeda Ventures in?

Almeda Ventures's product category is Venture Capital / HealthTech Investment. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CTechAugmedics raises $36 million led by Almeda Ventures for AR x-ray visionAugmedics raised $36 million in a round led by Almeda Ventures, with participation from HI.I.G. Capital, HCA, and XR Investment. The funds will support U.S. marketing, next-generation device development, and CE marking in Europe. The company's AR x-ray system has enabled 250 spinal cord surgeries since 2020.IFTTTClal Biotech to form $100m SPACClal Biotech announced a $100 million SPAC to acquire a pharmaceutical or digital health company, and will spin off its Anatomy medical technology funds to Almeda Ventures. The company also declared a NIS 36 million dividend and a NIS 9.3 million buyback program.PR NewswireNurami Medical Raises up to $6 Million Round in Series B Funding Led by Almeda VenturesNurami Medical, a medical device R&D company based in Haifa, Israel, has completed a fundraising round of up to $6 million in Series B funding led by Almeda Ventures, with participation from Glenrock and additional investors. The financing will fund completion of the ongoing clinical trial for ArtiFascia, the company's first product for dura repair following cranial neurosurgery, and support regulatory approval processes from the FDA and CE. The company, established in 2014, has previously raised $5 million from various investors and the Israel Innovation Authority.PR NewswireBioProtect Announces Final Closing of Equity Financing at $25M To Protect Prostate Cancer PatientsBioProtect announced the final closing of a $25 million Series D equity financing round led by Almeda Ventures and Vincent Tchenguiz, with participation from Peregrine Ventures, KB Investments, and Triventures. The proceeds will fund the ongoing multicenter FDA clinical trial for its lead product, ProSpace™ balloon spacer, which is designed to protect prostate cancer patients undergoing radiation therapy.